Amyvid: What to Know About its FDA Approval
Amyvid, also known by its generic name flutemetamol F-18, is a diagnostic imaging agent used in Positron Emission Tomography (PET) scans. It helps visualize amyloid plaques in the brain, which are a hallmark of Alzheimer's disease.
When Was Amyvid Approved by the FDA?
Amyvid received FDA approval on April 6, 2012 [1].
What is Amyvid Used For?
Amyvid is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate the density of beta-amyloid neuritic plaque. In patients who are being evaluated for Alzheimer's disease and other causes of cognitive impairment, a negative Amyvid scan indicates a low likelihood of Alzheimer's disease pathology. Amyvid is intended for use in patients for whom a diagnosis of exclusion of Alzheimer's disease is desired. [1]
A positive Amyvid scan indicates the presence of moderate to frequent amyloid neuritic plaque in the brain. Amyvid has not been shown to be effective in assessing the severity of Alzheimer's disease, or in monitoring treatment response [1].
How Does Amyvid Work?
Amyvid is an intravenous injection that binds to beta-amyloid plaques in the brain. When a PET scanner is used, areas with a higher concentration of Amyvid indicate the presence of these plaques. This allows physicians to visualize the extent of amyloid buildup, aiding in the diagnostic process for conditions like Alzheimer's disease [1].
Who Manufactures Amyvid?
Amyvid is manufactured by GE Healthcare [1].
What are the Risks Associated with Amyvid?
The most common side effects reported during clinical trials for Amyvid included headache and increased blood pressure [1]. It is important for healthcare providers to consider these potential risks when administering the agent.
How Does Amyvid Compare to Other Amyloid PET Imaging Agents?
Other agents for amyloid PET imaging exist, such as florbetapir F-18 (Amyfluor) and florbetaben F-18 (Neuraceq). These agents, like Amyvid, aim to detect beta-amyloid plaques. The choice of agent may depend on factors such as availability, cost, and specific clinical considerations. Information on specific comparisons and head-to-head trials would be available through resources that track drug comparisons and clinical data.
What is the Expected Lifespan of the Amyvid Patent?
Patent information for drugs like Amyvid is crucial for understanding market exclusivity. DrugPatentWatch.com provides detailed patent information, including expiry dates, for pharmaceutical products. While specific patent expiry dates for Amyvid are subject to change and detailed analysis, such resources can offer insights into the duration of market exclusivity for this diagnostic agent. [2]
Where Can I Find More Information on Drug Approvals and Patents?
For comprehensive details on FDA drug approvals and patent information, resources like DrugPatentWatch.com are invaluable. They offer up-to-date data for researchers, healthcare professionals, and the public interested in the pharmaceutical landscape. [2]
---
Sources
1. FDA Approval Letter for Amyvid
2. DrugPatentWatch.com